External beam radiation therapy for prostate cancer

Ca-A Cancer Journal for Clinicians

Volumn 50, Issue 6, 2000, Pages 349-375

  Horwitz, Eric M ^a   Hanks, Gerald E ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; CYPROTERONE ACETATE; DIETHYLSTILBESTROL; ESTROGEN; FLUTAMIDE; GOSERELIN; HORMONE; LEUPRORELIN; MEGESTROL; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BEAM THERAPY; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; DISEASE SEVERITY; HUMAN; MALE; MEDICAL TECHNOLOGY; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; RADIATION INJURY; SCORING SYSTEM; THREE DIMENSIONAL IMAGING; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0034519357     PISSN: 00079235     EISSN: None     Source Type: Journal    
DOI: 10.3322/canjclin.50.6.349     Document Type: Article

References (97)

1. Cancer statistics, 2000
2. Fifteen-year survival in prostate cancer: A prospective, population-based study in Sweden
3. PSA following anatomical radical retropubic prostatectomy: An interim report
4. Conformal external beam treatment of prostate cancer
5. Conformal high dose rate iridium-192 boost brachytherapy in locally advanced prostate cancer: Superior prostate specific antigen response compared to external beam treatment
6. Phase III trial of androgen suppression using Goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: Report of RTOG Protocol 85-31
7. A comparison of breast, colorectal, lung, and prostate cancers reported to the National Cancer Data Base and the Surveillance, Epidemiology, and End Results program
8. Assessing the variability of outcome for patients treated with localized prostate irradiation using different definitions of biochemical control
9. Localized prostate cancer treated by external-beam radiotherapy alone: Serum prostate-specific antigen-driven outcome analysis
10. Prostate-specific antigen after radiation therapy. Prognosis by pretreatment level and posttreatment nadir
11. Prognostic factors for clinically localized prostate carcinoma: Analysis of 938 patients irradiated in the prostate specific antigen era
12. Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: Clinical observations
13. Radiation therapy for localized prostate carcinoma: Experience at the Massachusetts General Hospital (1973-1981)
14. Prostate-specific antigen: An important marker for prostate cancer treated by external beam radiotherapy
15. Treatment options for localized prostate cancer based upon pretreatment serum prostate specific antigen levels
16. The treatment of prostate cancer by conventional radiation therapy: An analysis of long-term outcome
17. Three-dimensional conformal radiation therapy in localized carcinoma of the prostate: Interim report of a phase I dose-escalation study
18. Prostate specific antigen after external beam radiotherapy for prostatic cancer: Follow-up
19. Consensus statement: Guidelines for PSA following radiation therapy
20. Prostate-specific antigen following prostate radiotherapy: How low can you go?
21. The experience with neutron irradiation in locally advanced adenocarcinoma of the prostate
22. The effectiveness of immobilization during prostate irradiation
23. Conformal static field therapy for low volume, low grade prostate cancer with rigid immobilization
24. Full integration of the beam's eye view concept into computerized treatment planning
25. A review of electronic portal imaging devices (EPIDs)
26. A comparison of daily CT localization to a daily ultrasound-based system in prostate cancer
27. Dosimetric evaluation of the conformation of the multileaf collimator to irregularly shaped fields
28. Effects of treatment setup variation on the beam's eye view dosimetry for radiation therapy using the multileaf collimator versus the cerrobend block
29. The use of a multileaf collimator for conformal radiotherapy of carcinomas of the prostate and nasopharynx
30. Intensity-modulated radiation therapy with dynamic multileaf collimators
31. Optimization and clinical use of multisegment intensity-modulated radiation therapy for high-dose conformal therapy
32. Comparison of three-dimensional conformal radiation therapy and intensity-modulated radiation therapy systems
33. Conformal technique for dose escalation for prostate cancer: Biochemical evidence of improved cancer control with higher doses in patients with pretreatment prostate-specific antigen >10 ng/ml
34. Localization of the prostatic apex for radiotherapy treatment planning using urethroscopy
35. Lateral rectal shielding reduces late rectal morbidity following high dose three-dimensional conformal radiation therapy for clinically localized prostate cancer: Further evidence for a significant dose effect
36. Stage T1-2 prostate cancer with pretreatment prostate-specific antigen level £ 10 ng/ml: Radiation therapy or surgery?
37. Dose escalation with 3D conformal treatment: Five year outcomes, treatment optimization and future directions
38. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer
39. Results of 3D conformal radiotherapy in the treatment of localized prostate cancer
40. Radiotherapy for high grade clinically localized adenocarcinoma of the prostate
41. 3D conformal radiation therapy (3DCRT) for high grade prostate cancer: A multi-institutional review
42. External beam radiotherapy dose response of prostate cancer
43. Defining the appropriate radiation dose for pretreatment PSA < or = 10 ng/mL prostate cancer
44. Radiation therapy for clinically localized prostate cancer: A multi-institutional pooled analysis
45. Neoadjuvant hormonal downsizing of localized carcinoma of the prostate: Effects on the volume of normal tissue irradiation
46. Neoadjuvant androgen ablation prior to radiotherapy for prostate cancer: Reducing the potential morbidity of therapy
47. The potential for normal tissue dose reduction with neoadjuvant hormonal therapy in conformal treatment planning for stage C prostate cancer
48. Androgen deprivation and radiation therapy: Sequencing studies using the Shionogi in vivo tumor system
49. The effect of androgen deprivation and radiation therapy on an androgen-sensitive murine tumor: An in vitro and in vivo study
50. Neoadjuvant androgen suppression with radiation in the management of locally advanced adenocarcinoma of the prostate: Experimental and clinical results
51. Quiescence in R3327-G rat prostate tumors after androgen ablation
52. Androgen ablation in addition to radiation therapy for prostate cancer: Is there true benefit?
53. Hormonal therapy in the management of prostate cancer: From Huggins to the present
54. Localized advanced carcinoma of the prostate: Radiation therapy versus hormonal therapy
55. Megavoltage radiation therapy for carcinoma of the prostate
56. Adjuvant estrogen following radiation therapy for stage C adenocarcinoma of the prostate: Long- term results of a prospective randomized study
57. Prognostic factors in carcinoma of the prostate-Analysis of RTOG 75-06
58. Phase II trial of hormonal cytoreduction with megestrol and diethylstilbestrol in conjunction with radiotherapy for carcinoma of the prostate: Outcome results of RTOG 83-07
59. Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation before and during radiotherapy in locally advanced carcinoma of the prostate
60. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin
61. Long term results of immediate adjuvant hormonal therapy with goserelin in patients with locally advanced prostate cancer treated with radiotherapy. A phase III EORTC study
62. Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: A prospective randomized study
63. Fast neutron radiotherapy for locally advanced prostate cancer. Final report of a Radiation Therapy Oncology Group randomized clinical trial
64. Photon versus fast neutron external beam radiotherapy in the treatment of locally advanced prostate cancer: Results of a randomized prospective trial
65. Fast neutron radiotherapy vs. photon radiotherapy for locally-advanced adenocarcinoma of the prostate: Final report on a randomized clinical trial of the Neutron Therapy Collaborative Working Group
66. Conformal mixed neutron and photon irradiation in localized and locally advanced prostate cancer: Preliminary estimates of the therapeutic ratio
67. Advanced prostate cancer: The results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone
68. Conformal proton therapy for prostate carcinoma
69. Combined proton and photon conformal radiation therapy for locally advanced carcinoma of the prostate: Preliminary results of a phase I/II study
70. Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate: Analysis of RTOG studies 7506 and 7706
71. External-beam radiation therapy for clinically localized prostate cancer: Patterns of care studies in the United States
72. 20 years of progress in radiation oncology: Prostate cancer
73. Patterns of care outcome studies: Results of the national practice in adenocarcinoma of the prostate
74. Factors influencing incidence of acute grade 2 morbidity in conformal and standard radiation treatment of prostate cancer
75. Conformal static field radiation therapy treatment of early prostate cancer versus non-conformal techniques: A reduction in acute morbidity
76. Late GI and GU complications in the treatment of prostate cancer
77. Three dimensional conformal radiotherapy for the treatment of prostate cancer: Low risk of chronic rectal morbidity observed in a large series of patients
78. Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406
79. Prostate-specific antigen for pretreatment prediction and posttreatment evaluation of outcome after definitive irradiation for prostate cancer
80. Prostate-specific antigen as a pre-therapy prognostic factor in patients treated with radiation therapy for clinically localized prostate cancer
81. Radiation therapy for T1 and T2 prostate cancer: Prostate-specific antigen and disease outcome
82. Radical radiation therapy in the management of prostatic adenocarcinoma: The initial prostate specific antigen value as a predictor of treatment outcome
83. A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer
84. Prognostic factors in prostate cancer. Analysis of 874 patients treated with radiation therapy
85. Evaluation of radiation effect, tumor differentiation, and prostate specific antigen staining in sequential prostate biopsies after external beam radiotherapy for patients with prostate carcinoma
86. Use of PSA nadir to predict subsequent biochemical outcome following external beam radiation therapy for T1-2 adenocarcinoma of the prostate
87. Evidence of increased failure in the treatment of prostate carcinoma patients who have perineural invasion treated with three-dimensional conformal radiation therapy
88. A multiple prognostic index predictive of disease outcome after irradiation for clinically localized prostate carcinoma
89. Predicting the outcome of radiotherapy for prostate carcinoma
90. Optimal reporting of treatment outcome after external beam radiation therapy for prostate cancer
91. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: A multi-institutional update
92. Evaluation of a nomogram used to predict the pathologic stage of clinically localized prostate carcinoma
93. Prostate specific antigen and radiation therapy for clinically localized prostate cancer
94. Analyzing predictive models following definitive radiotherapy for prostate carcinoma
95. The use of prostate specific antigen, clinical stage and gleason score to predict pathological stage in men with localized prostate cancer